Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Decline in Short Interest

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) saw a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 837,200 shares, a decline of 33.6% from the November 15th total of 1,260,000 shares. Approximately 1.0% of the shares of the stock are short sold. Based on an average trading volume of 1,610,000 shares, the short-interest ratio is presently 0.5 days.

Analyst Ratings Changes

Several analysts have recently commented on UNCY shares. HC Wainwright reiterated a "buy" rating and issued a $2.50 price target on shares of Unicycive Therapeutics in a research report on Tuesday, November 12th. Benchmark reiterated a "speculative buy" rating and set a $3.00 target price on shares of Unicycive Therapeutics in a report on Friday, November 22nd. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $5.13.

Institutional Trading of Unicycive Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of UNCY. XTX Topco Ltd acquired a new position in shares of Unicycive Therapeutics during the 3rd quarter valued at about $29,000. Virtu Financial LLC grew its holdings in Unicycive Therapeutics by 566.8% in the third quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock valued at $30,000 after purchasing an additional 62,881 shares during the period. Bleakley Financial Group LLC acquired a new position in Unicycive Therapeutics during the third quarter worth approximately $33,000. Acuta Capital Partners LLC purchased a new position in Unicycive Therapeutics during the third quarter worth approximately $807,000. Finally, Walleye Capital LLC acquired a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at $2,040,000. 40.42% of the stock is owned by hedge funds and other institutional investors.

Unicycive Therapeutics Trading Down 3.4 %

Shares of NASDAQ UNCY traded down $0.03 during midday trading on Friday, reaching $0.71. 668,889 shares of the stock were exchanged, compared to its average volume of 1,246,560. The stock has a 50 day moving average price of $0.53 and a 200-day moving average price of $0.49. The company has a market capitalization of $74.16 million, a P/E ratio of -0.74 and a beta of 2.36. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.82.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.